focus -WSS

focus

author：explore 2025-09-30 16:27:47 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Mike Pence clashes with Tucker Carlson in Iowa

focus

WSS

Trump team launching legal defense fund to help pay legal bills

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Celiac disease study examines precisely how gluten triggers injury

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

5 wounded, 2 critically, in Michigan shopping center shooting

entertainment

focus

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Celiac disease study examines precisely how gluten triggers injury

At least 13 dead in Texas as scorching temps continue

Argenx drug significantly slows progression of nerve disorder

Bright Health sells Medicare Advantage business to Molina

Trump team launching legal defense fund to help pay legal bills

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Grail faces three suits alleging harassment, retaliation

Sports medicine is finally prioritizing gender equality

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

entertainment

Congress likely to miss an opportunity to fix drug shortages issue

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Many immigrants are left out of maternal health programs

Doctors in states that ban abortion can still help patients

Teacher posts viral 'school supply rant' with advice for parents

focus

entertainment

focus

explore